HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.